Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer [Phase 2]
Phase 2 clinical trial update for PF-06463922 in crizotinib-pretreated ROS1-positive non-small-cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating paclitaxel albumin-stabilized nanoparticle formulation in patients with previously treated advanced non-small cell …
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients [Phase 2]
A Phase 2 clinical trial evaluating retreatment with an EGFR tyrosine kinase inhibitor in EGFR mutation–positive non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating pembrolizumab in EGFR-mutant, tyrosine kinase inhibitor–naive advanced non-small cell lung cancer has completed;…
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery [Phase 1, Phase 2]
Clinical trial update on veliparib with or without radiation therapy, carboplatin, and paclitaxel in patients with unresectable Stage III no…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]
Phase I/II clinical study update for SAF-189s in NSCLC, with phases including Phase 1 and Phase 2; current status is UNKNOWN.
-
FDA approval · 2021-07-08FDA Approved: ERLOTINIB HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's Erlotinib Hydrochloride original application (ANDA214719), authorizing a generic Erlotinib hy…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation [Phase 3]
Phase III study comparing almonertinib to platinum-based chemotherapy as first-line therapy in locally advanced or metastatic non-small cell…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants [Phase 2]
Phase 2 trial update examining single-agent niraparib and niraparib plus PD-1 inhibitors in non-small cell lung cancer has completed with re…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC [Phase 2]
Phase 2 study evaluating the combination of almonertinib with concurrent chemoradiotherapy in unresectable stage III non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy [NA]
Clinical trial update describing an adaptive radiotherapy approach using photon and proton beams; results posted after completion.
-
FDA approval · 2021-07-01FDA Approved: DOCETAXEL — Original Application (Gland Pharma Limited)
FDA approves Gland Pharma Limited's generic docetaxel as an Original Application, adding a new generic option for cancer chemotherapy.
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with apatinib for advanced non-squamous non-small cell lung cancer previously treated w…
-
CLINICAL_TRIALS trial_result · 2021-06-28Clinical Trial Update: Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients [Phase 2]
Phase 2 trial update on neoadjuvant immunotherapy combined with chemotherapy for stage I-IIIB non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC [Phase 3]
Phase 3 trial comparing IBI308 versus Docetaxel in advanced or metastatic non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC [Phase 2]
Phase 2 neoadjuvant trial evaluating camrelizumab with nab-paclitaxel and carboplatin in stage IB-IIIA non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC [Phase 2]
Phase 2 trial evaluating selumetinib with pemetrexed and platinum in advanced/metastatic KRAS wildtype or unknown non-squamous non-small cel…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating erlotinib with or without investigational drug U3-1287 in advanced non-small cell lung cancer has completed, with…
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating napabucasin plus weekly paclitaxel versus paclitaxel alone in advanced previously treated non-squamous non-small ce…
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating radiation therapy for stage I-II non-small cell lung cancer has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial update exploring nivolumab in combination with EGF816 and with INC280 for previously treated non-small cell lung cancer; study…
-
CLINICAL_TRIALS trial_result · 2021-06-10Clinical Trial Update: Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) [Phase 1, Phase 2]
Clinical trial update for NSCLC patients with EGFR mutations (Del 19 or L858R +/- T790M); study phases 1 and 2, terminated with results post…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. [Phase 2]
Phase 2 trial update on pembrolizumab as first-line treatment for advanced NSCLC with low PD-L1 expression.
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Osimertinib Study in Indian Patients [Phase 4]
Phase 4 trial update of osimertinib in Indian patients with non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery [Phase 2]
Phase 2 clinical trial evaluating pre-operative gefitinib in resectable EGFR mutation-positive non-small cell lung cancer with sector sequen…